Rapport Therapeutics Q2 2024 GAAP EPS $(1.70) Misses $(0.68) Estimate
Portfolio Pulse from Benzinga Newsdesk
Rapport Therapeutics reported a Q2 2024 GAAP EPS of $(1.70), missing the estimate of $(0.68).
August 08, 2024 | 11:57 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Rapport Therapeutics reported a Q2 2024 GAAP EPS of $(1.70), significantly missing the estimate of $(0.68). This earnings miss could negatively impact the stock price in the short term.
The significant miss in earnings per share (EPS) compared to the estimate is likely to lead to a negative reaction from investors, causing a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100